Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants.

doi:10.1016/j.vaccine.2013.07.057

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants.

Vaccine - 23 Sept 2013

Melamed Sharon, Wyatt Linda S, Kastenmayer Robin J, Moss Bernard

Abstract excerpt

Modified vaccinia virus Ankara (MVA) is being widely investigated as a safe smallpox vaccine and as an expression vector to produce vaccines against other infectious diseases and cancer. MVA was isolated following more than 500 passages in chick embryo fibroblasts and suffered several major deletions and numerous small mutations resulting in replication defects in human and most other mammalian cells as well as...

Topics

Animals
Disease Models, Animal
Female
Host Specificity
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Mice, Inbred ICR
Mutation
Recombination, Genetic
Smallpox Vaccine
Vaccinia
Vaccinia virus
Virulence
Virus Replication

Source

Open in PubMed Open full text

Identifiers

PMID: 23928462
DOI: 10.1016/j.vaccine.2013.07.057
PMCID: PMC3787882

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics